Active Ingredient History
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Hematopoietic Stem Cell Transplantation (approved 2011)
Acne Vulgaris (Phase 3)
Adrenoleukodystrophy (Phase 1/Phase 2)
Allografts (Phase 2)
alpha-Mannosidosis (Phase 1/Phase 2)
Amputation (Phase 1)
Amyotrophic Lateral Sclerosis (Phase 1/Phase 2)
Anemia (Phase 4)
Anemia, Aplastic (Phase 2)
Anemia, Diamond-Blackfan (Phase 2)
Anemia, Refractory (Phase 3)
Anemia, Sickle Cell (Phase 2)
Antigens, CD (Phase 1)
Arterial Occlusive Diseases (Phase 1)
Arteriosclerosis (Phase 1)
Arthritis, Psoriatic (Phase 2)
Arthritis, Rheumatoid (Phase 1)
Atherosclerosis (Phase 1)
Autoimmune Diseases (Phase 2)
Bone Diseases (Early Phase 1)
Bone Marrow Cells (Phase 2)
Breast Neoplasms (Phase 2)
Burkitt Lymphoma (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Cardiovascular Diseases (Phase 1)
Central Nervous System Diseases (Phase 1)
Chromosome Aberrations (Phase 2)
Chronic Disease (Phase 2)
Common Variable Immunodeficiency (Phase 2)
Crohn Disease (Phase 2)
Diploidy (Phase 2)
Enterocolitis, Neutropenic (Phase 1/Phase 2)
Epstein-Barr Virus Infections (Phase 2)
Fanconi Anemia (Phase 2)
GATA2 Transcription Factor (Phase 2)
Genetic Diseases, Inborn (Phase 2)
Glioblastoma (Phase 2/Phase 3)
Graft vs Host Disease (Phase 4)
Granulomatous Disease, Chronic (Phase 2)
Gynatresia (Phase 2)
Healthy Volunteers (Phase 1)
Heart Diseases (Phase 1)
Heart Failure (Phase 2)
Hematologic Neoplasms (Phase 2)
Hematopoietic Stem Cell Transplantation (Phase 2)
Hemoglobinuria, Paroxysmal (Phase 2)
Hemophilia A (Phase 1)
Hodgkin Disease (Phase 3)
Idiopathic Interstitial Pneumonias (Phase 1/Phase 2)
Idiopathic Pulmonary Fibrosis (Phase 1/Phase 2)
Immune System Diseases (Phase 2)
Immune Tolerance (Phase 1)
Immunoglobulin M (Phase 2)
Infections (Phase 2)
Infertility (Phase 2)
Infertility, Female (Phase 2)
Inflammation (Phase 2)
Inflammatory Bowel Diseases (Phase 1)
Intermittent Claudication (Phase 2/Phase 3)
Intestinal Neoplasms (Phase 2)
Intraocular Lymphoma (Phase 2)
Ischemia (Phase 1)
Ischemic Stroke (Phase 1/Phase 2)
Kidney Neoplasms (Phase 2)
Kidney Transplantation (Phase 2)
Leukemia (Phase 4)
Leukemia, B-Cell (Phase 2)
Leukemia, Biphenotypic, Acute (Phase 2)
Leukemia, Eosinophilic, Acute (Phase 2)
Leukemia, Hairy Cell (Phase 2)
Leukemia, Large Granular Lymphocytic (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Mast-Cell (Phase 2)
Leukemia, Monocytic, Acute (Phase 3)
Leukemia, Myeloid, Acute (Phase 3)
Leukemia, Myeloid, Chronic-Phase (Phase 3)
Leukemia, Myelomonocytic, Acute (Phase 3)
Leukemia, Myelomonocytic, Chronic (Phase 3)
Leukemia, Myelomonocytic, Juvenile (Phase 3)
Leukemia, Neutrophilic, Chronic (Phase 2)
Leukemia, Plasma Cell (Phase 2)
Leukemia, Prolymphocytic (Phase 3)
Leukemia, Prolymphocytic, B-Cell (Phase 2)
Leukemia, Prolymphocytic, T-Cell (Phase 3)
Leukodystrophy, Globoid Cell (Phase 1/Phase 2)
Leukodystrophy, Metachromatic (Phase 1/Phase 2)
Liver Cirrhosis (Phase 2)
Liver Failure (Phase 2)
Lung Diseases (Early Phase 1)
Lung Diseases, Interstitial (Phase 1/Phase 2)
Lupus Erythematosus, Systemic (Phase 1)
Lupus Nephritis (Phase 1)
Lymphohistiocytosis, Hemophagocytic (Phase 2)
Lymphoma (Phase 4)
Lymphoma, B-Cell (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 3)
Lymphoma, Non-Hodgkin (Phase 3)
Lymphoma, T-Cell (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 2)
Lymphomatoid Granulomatosis (Phase 2)
Lymphoproliferative Disorders (Phase 2)
Mastocytosis (Phase 2)
Melanoma (Phase 1)
Motor Neuron Disease (Phase 1)
Mucopolysaccharidoses (Phase 1/Phase 2)
Mucopolysaccharidosis I (Phase 1/Phase 2)
Mucositis (Phase 3)
Multiple Myeloma (Phase 4)
Myelodysplastic Syndromes (Phase 4)
Myeloproliferative Disorders (Phase 3)
Neoplasm Metastasis (Phase 2/Phase 3)
Neoplasm, Residual (Phase 2)
Neoplasms (Phase 2)
Neuroblastoma (Phase 2)
Neurodegenerative Diseases (Phase 1)
Neuromuscular Diseases (Phase 1)
Neutropenia (Phase 3)
Niemann-Pick Diseases (Phase 1/Phase 2)
Orthopedic Procedures (Phase 1)
Osteoarthritis (Phase 1/Phase 2)
Osteoarthritis, Knee (Phase 1/Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 1)
Parkinson Disease (Phase 1/Phase 2)
Pathologic Processes (Phase 2)
Pelizaeus-Merzbacher Disease (Phase 1/Phase 2)
Peripheral Arterial Disease (Phase 1)
Peripheral Vascular Diseases (Phase 2/Phase 3)
Plasmacytoma (Phase 2)
Polycythemia Vera (Phase 2)
Precancerous Conditions (Phase 2)
Primary Immunodeficiency Diseases (Phase 2)
Primary Myelofibrosis (Phase 3)
Psoriasis (Phase 2)
Respiratory Distress Syndrome (Phase 2)
Sandhoff Disease (Phase 1/Phase 2)
Sarcoma (Phase 2)
Sarcoma, Myeloid (Phase 2)
Scleroderma, Systemic (Phase 2)
Sclerosis (Phase 1/Phase 2)
Sepsis (Phase 2)
Severe Combined Immunodeficiency (Phase 2)
Sezary Syndrome (Phase 2)
Shock (Phase 2)
Shock, Septic (Phase 2)
Shwachman-Diamond Syndrome (Phase 2)
Smoldering Multiple Myeloma (Phase 1/Phase 2)
Spinal Cord Injuries (Phase 1)
Stem Cells (Phase 1)
Stroke (Phase 2/Phase 3)
Systemic Inflammatory Response Syndrome (Phase 2)
Tay-Sachs Disease (Phase 1/Phase 2)
Testicular Neoplasms (Phase 2)
Thrombocythemia, Essential (Phase 2)
Thrombocytopenia (Phase 2)
Tissue Adhesions (Phase 2)
Tissue Donors (Phase 2)
Translocation, Genetic (Phase 2)
Transplantation (Phase 2)
Transplantation, Autologous (Phase 2)
Transplantation, Homologous (Phase 2)
Vascular Diseases (Phase 1)
Vascular Grafting (Phase 2)
Waldenstrom Macroglobulinemia (Phase 3)
Wiskott-Aldrich Syndrome (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue